X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE ASTRAZENECA PHARMA TTK HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 51.5 105.3 48.9% View Chart
P/BV x 9.5 15.0 63.3% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 TTK HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
ASTRAZENECA PHARMA
Mar-14
TTK HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6631,285 51.6%   
Low Rs399634 62.9%   
Sales per share (Unadj.) Rs535.6189.6 282.5%  
Earnings per share (Unadj.) Rs15.9-0.2 -7,832.0%  
Cash flow per share (Unadj.) Rs20.03.8 520.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs137.668.6 200.5%  
Shares outstanding (eoy) m7.7725.00 31.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.05.1 19.6%   
Avg P/E ratio x33.3-4,712.7 -0.7%  
P/CF ratio (eoy) x26.5249.6 10.6%  
Price / Book Value ratio x3.914.0 27.6%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m4,12723,988 17.2%   
No. of employees `0001.71.6 109.6%   
Total wages/salary Rs m6071,605 37.8%   
Avg. sales/employee Rs Th2,436.73,040.2 80.1%   
Avg. wages/employee Rs Th355.21,029.2 34.5%   
Avg. net profit/employee Rs Th72.5-3.3 -2,221.8%   
INCOME DATA
Net Sales Rs m4,1624,740 87.8%  
Other income Rs m6192 66.4%   
Total revenues Rs m4,2234,832 87.4%   
Gross profit Rs m197-130 -151.8%  
Depreciation Rs m32101 31.3%   
Interest Rs m300-   
Profit before tax Rs m197-139 -141.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m735 1,430.3%   
Profit after tax Rs m124-5 -2,434.2%  
Gross profit margin %4.7-2.7 -172.9%  
Effective tax rate %37.0-3.7 -1,010.0%   
Net profit margin %3.0-0.1 -2,772.2%  
BALANCE SHEET DATA
Current assets Rs m1,6292,726 59.7%   
Current liabilities Rs m1,0582,435 43.4%   
Net working cap to sales %13.76.1 223.1%  
Current ratio x1.51.1 137.5%  
Inventory Days Days3074 40.4%  
Debtors Days Days3441 82.4%  
Net fixed assets Rs m5561,035 53.7%   
Share capital Rs m7850 155.4%   
"Free" reserves Rs m878942 93.2%   
Net worth Rs m1,0691,716 62.3%   
Long term debt Rs m1590-   
Total assets Rs m2,3994,156 57.7%  
Interest coverage x7.6NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x1.71.1 152.1%   
Return on assets %6.4-0.1 -5,233.7%  
Return on equity %11.6-0.3 -3,906.4%  
Return on capital %18.50-  
Exports to sales %0.85.7 13.9%   
Imports to sales %1.46.5 21.7%   
Exports (fob) Rs m33270 12.2%   
Imports (cif) Rs m58306 19.0%   
Fx inflow Rs m33375 8.8%   
Fx outflow Rs m63470 13.4%   
Net fx Rs m-30-96 31.7%   
CASH FLOW
From Operations Rs m127-8 -1,563.0%  
From Investments Rs m-146-146 100.2%  
From Financial Activity Rs m22862 2.5%  
Net Cashflow Rs m3709 0.4%  

Share Holding

Indian Promoters % 65.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 5.2 15.7 33.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 9.1 283.5%  
Shareholders   12,723 12,856 99.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   GSK PHARMA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Feb 16, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 8-QTR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS